Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

16.03 -0.07 (-0.43%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,671,332
Open 16.04
Bid (Size) 14.44 (3)
Ask (Size) 16.21 (1)
Prev. Close 16.10
Today's Range 15.94 - 16.07
52wk Range 12.28 - 16.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
 
Via Benzinga

Performance

YTD
+1.71%
+1.71%
1 Month
+2.76%
+2.76%
3 Month
+21.26%
+21.26%
6 Month
+11.94%
+11.94%
1 Year
+10.86%
+10.86%

More News

Read More
Current Report: Takeda Pharmaceutical (TAK)
Via Talk Markets
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
Via Benzinga
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
From HUTCHMED (China) Limited
Via Globe NewsWire
A Bullish Sign Appears On Takeda Pharmaceutical's Chart
Via Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Via Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Via Benzinga
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Named Global Top Employer for Sixth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Via Talk Markets
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
Via Benzinga
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Via Benzinga
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
From Takeda Pharmaceutical Company Limited
Via Business Wire
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Via The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
Via Investor's Business Daily
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.